Education
About Us
Working with TipRanks
Follow Us
NanoViricides (NNVC)
:NNVC
NNVC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.94 - $1.92
Previous CloseN/A
Volume409.80K
Average Volume (3M)128.68K
Market Cap
$22.82M
Enterprise Value$16.71M
Total Cash (Recent Filing)$2.54M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.44
Next Earnings
Nov 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding16,072,000
10 Day Avg. Volume132,763
30 Day Avg. Volume128,679
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio-3.39
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-21.61
Enterprise Value/Ebitda-1.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NanoViricides News
NNVC FAQ
What was NanoViricides’s price range in the past 12 months?
NanoViricides lowest stock price was $0.94 and its highest was $1.92 in the past 12 months.
What is NanoViricides’s market cap?
NanoViricides’s market cap is $22.82M.
When is NanoViricides’s upcoming earnings report date?
NanoViricides’s upcoming earnings report date is Nov 24, 2025 which is in 56 days.
How were NanoViricides’s earnings last quarter?
Currently, no data Available
Is NanoViricides overvalued?
According to Wall Street analysts NanoViricides’s price is currently Overvalued.
Does NanoViricides pay dividends?
NanoViricides does not currently pay dividends.
What is NanoViricides’s EPS estimate?
NanoViricides’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoViricides have?
NanoViricides has 16,072,000 shares outstanding.
What happened to NanoViricides’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NanoViricides?
Currently, no hedge funds are holding shares in NNVC
Company Description
NanoViricides
NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
Technical Analysis
Ownership Overview
6.55%
Insiders
4.24% Mutual Funds
0.90% Other Institutional Investors
85.36% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---